Bone marrow fibre content in acute myeloid leukaemia before and after treatment.
Bone marrow fibre content was studied in 34 patients with acute myeloid leukaemia at presentation and subsequently after chemotherapy and at complete remission. The findings indicate that: some degree of marrow fibrosis is present in about one third of the patients with acute myeloid leukaemia at presentation; effective antileukaemia treatment may result in reversal of marrow fibrosis; and increase in marrow fibre content at diagnosis does not affect haemopoietic regeneration after treatment and achievement of complete remission.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001853:Bone Marrow / Q000032:analysis / Q000473:pathology*; D003094:Collagen / Q000032:analysis; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000473:pathology*; D011034:Podophyllotoxin / Q000008:administration & dosage; D055728:Primary Myelofibrosis / Q000473:pathology; D012155:Reticulin / Q000032:analysis; D013866:Thioguanine / Q000008:administration & dosage
D012155:Reticulin; D003561:Cytarabine; D003094:Collagen; D013866:Thioguanine; D011034:Podophyllotoxin; D003630:Daunorubicin